Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
about
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Alterations of consciousness and mystical-type experiences after acute LSD in humans.Clinical applications of hallucinogens: A review.Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI)Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions.The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.An online survey of tobacco smoking cessation associated with naturalistic psychedelic use.Psychedelics as Medicines: An Emerging New Paradigm.Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.Long-term follow-up of psilocybin-facilitated smoking cessation.Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequencesThe Mechanisms of Psychedelic Visionary Experiences: Hypotheses from Evolutionary PsychologyLong-lasting subjective effects of LSD in normal subjects.On the primacy and irreducible nature of first-person versus third-person information.The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016.Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.Unifying Theories of Psychedelic Drug Effects.The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016).DMT Models the Near-Death ExperiencePredicting Responses to Psychedelics: A Prospective Study
P2860
Q30843010-E8ED0FD8-2F87-47EA-9F8B-752C9FA1B4BAQ30847957-6388C2BB-DAFF-4425-916B-E84037437441Q34535259-55377CAE-67BF-4070-AF3C-E2E1A9ADED32Q36999815-4B353FF3-ACC9-4787-9674-E7A62BA0A5BFQ37722650-61FEC74E-C3C8-4B7B-B58B-83BCDAF530F6Q38645170-C4A00F67-928A-4753-80AA-6585432A3AF1Q38794300-FAECEF96-D81E-4E71-83C1-B4A7A580FD47Q39016513-2B132692-4229-46E1-BF22-FC116ECF4F8DQ39055247-B93A9F47-9AEA-4667-A854-78634E0D4296Q39548034-57DBE992-F992-488C-8288-276232E73BDDQ39577435-82C99549-6C91-4966-B52A-0BCA66F0BED2Q41343321-AD70DF99-7A00-4496-9B81-2F17711F1132Q42369129-4D03E949-C4BD-4DA9-88D4-399BED456C5CQ47691384-D6FB1119-B51A-483A-BF79-139C162981DBQ47864136-1647308B-8F79-49E8-96A6-3995F60A89E9Q48314730-B324B87C-8B48-4453-93FA-6E9B3EF19183Q50095081-BFF3E0A2-8DD9-4895-88D2-566307AB56C0Q50109109-2FD23A29-417C-456E-AA18-5A8BA3590E12Q52641641-2EC00766-A1CD-40A1-8932-6623BA8BC959Q53439351-9C182510-37B9-4A00-BEC2-BD70BB72F5AAQ53439357-2C2DAD56-BB68-4397-8A4E-2644161BA5C8Q53843342-E064C3DE-6647-4FDF-96DD-5084E1CB056CQ56097236-FE9D788A-078C-489A-809F-8CCF8071CF74Q59137436-166FE11E-E612-418F-844C-38D13B241D39
P2860
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
description
2015 nî lūn-bûn
@nan
2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Validation of the revised Myst ...... ntal sessions with psilocybin.
@ast
Validation of the revised Myst ...... ntal sessions with psilocybin.
@en
type
label
Validation of the revised Myst ...... ntal sessions with psilocybin.
@ast
Validation of the revised Myst ...... ntal sessions with psilocybin.
@en
prefLabel
Validation of the revised Myst ...... ntal sessions with psilocybin.
@ast
Validation of the revised Myst ...... ntal sessions with psilocybin.
@en
P2860
P356
P1476
Validation of the revised Myst ...... ntal sessions with psilocybin.
@en
P2093
Matthew W Johnson
Roland R Griffiths
P2860
P304
P356
10.1177/0269881115609019
P407
P577
2015-10-06T00:00:00Z